The increasing prevalence of Hepatitis B infections serves as a significant driver in the global Hepatitis B infection market by creating a growing demand for effective diagnostic tools, vaccines, and antiviral treatments. As Hepatitis B is a major cause of liver diseases such as cirrhosis and liver cancer, the rising infection rates globally, particularly in regions with inadequate healthcare infrastructure, have heightened the need for prevention, management, and treatment options. The spread of chronic Hepatitis B infections, especially in low- and middle-income countries where awareness and vaccination programs are less established, further amplifies the market for immunization, antiviral therapies, and advanced diagnostic techniques. Also, pharmaceutical companies are investing in research and development of newer, more efficient antiviral drugs and vaccines to address the evolving strains of the virus. The rise in both acute and chronic cases, particularly in high-risk populations, has put pressure on healthcare systems to invest in improved diagnostics, vaccines, and antiviral therapies. Overall, the growing burden of Hepatitis B infection propels the demand for both therapeutic and preventive solutions, fueling market growth.
Access Full Report @ https://www.databridgemarketresearch.com/de/reports/global-hepatitis-b-infection-market
Data Bridge Market Research analyses that the Global Hepatitis B Treatment Market is expected to reach USD 18.21 billion by 2031 from USD 12.11 billion in 2023, growing with a CAGR of 5.2% in the forecast period of 2024 to 2031.
Key Findings of the Study
Technological Advancements in Diagnostics
Technological advancements in diagnostics play a pivotal role in driving the global Hepatitis B infection market by improving the accuracy, speed, and accessibility of Hepatitis B detection. Innovations such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and rapid diagnostic tests have enhanced the ability to identify Hepatitis B infections at earlier stages, including asymptomatic cases, which helps in timely intervention and treatment. These technologies allow for more precise quantification of viral load, enabling personalized treatment approaches and better monitoring of disease progression. The development of point-of-care diagnostic tools has also improved access to testing in remote and resource-limited regions, where Hepatitis B is more prevalent, significantly boosting market demand. Additionally, advanced diagnostic platforms integrated with artificial intelligence (AI) and machine learning (ML) are revolutionizing data analysis, allowing healthcare professionals to make faster, more informed decisions. As these technologies continue to evolve and become more cost-effective, they contribute to increased adoption across healthcare settings, further driving the global hepatitis B infection market.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable to 2016 – 2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Type (Chronic and Acute), Treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery)
|
|
Countries Covered
|
U.S., Canada and Mexico, China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Vietnam, New Zealand, Taiwan, Philippines, and rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Denmark, Norway, Finland, Poland Turkey, and rest of Europe, South Africa, Saudi Arabia, Egypt, Kuwait, Qatar, U.A.E., Oman, Bahrain, and rest of Middle east and Africa, Brazil, Argentina, and rest of South America
|
|
Market Players Covered
|
Gilead Sciences, Inc. (U.S.), GlaxoSmithKline plc (UK), Dynavax Technologies (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S.), Merck Sharp and Dohme Corp. (U.S.), Novartis AG (Switzerland), Arrowhead Pharmaceuticals Inc. (U.S.), Arbutus Biopharma (Canada), Teva Pharmaceuticals, Inc. (Israel), Zydus Pharmaceuticals (India), Aurobindo Pharma (India), Lupin Pharmaceuticals, Inc. (India) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
Global hepatitis B treatment market is categorized into two notable segments which are based on the type and treatment.
- On the basis of type, the market is segmented into chronic and acute
In 2024, the chronic segment of the type segment is expected to dominate the market
In 2024, the chronic segment is expected to dominate the market with market share of 85.91%, due to the long-term nature and complexity of managing chronic hepatitis B infections. Unlike acute hepatitis B, which often resolves on its own, chronic infections can persist for years and significantly increase the risk of severe liver complications, such as cirrhosis, liver failure, and hepatocellular carcinoma.
- On the basis of treatment, the market is segmented into vaccine, antiviral drugs, immune modulator drugs, and surgery
In 2024, the vaccine segment of the treatment segment is expected to dominate the global hepatitis B treatment market
In 2024, the vaccine segment is expected to dominate the market with a market share of 56.90%, because rising demand for automotive electronic components.
Major Players
Data Bridge Market Research analyses that Gilead Sciences, Inc. (U.S.), GlaxoSmithKline plc (UK), Dynavax Technologies (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company as major market players in this market.
Market Development
- In February 2024, GSK announced that the US FDA had granted Fast Track designation to bepirovirsen for chronic hepatitis B. This designation highlighted the unmet need for effective treatments and supported ongoing phase III trials for the investigational drug
- In March 2024, Gilead Sciences completed its acquisition of CymaBay Therapeutics for approximately USD 4.3 billion. This acquisition, announced in February 2024, integrated CymaBay’s investigational product, seladelpar, into Gilead’s liver disease portfolio
- In May 2024, Dynavax Technologies announced that the FDA issued a Complete Response Letter regarding its supplemental Biologics License Application for a four-dose HEPLISAV-B® regimen for adults on hemodialysis, citing insufficient data. The approved indication for HEPLISAV-B remains unchanged, while the European Commission approved the regimen in October 2023
- In September 2024, Gilead Sciences and Genesis Therapeutics announced a strategic collaboration to discover and develop novel small molecule therapies using Genesis’ GEMS AI platform. Gilead gained exclusive rights to develop and commercialize products from this partnership
Geographically, the countries covered in this market report are U.S., Canada and Mexico, China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Vietnam, New Zealand, Taiwan, Philippines, and rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Denmark, Norway, Finland, Poland Turkey, and rest of Europe, South Africa, Saudi Arabia, Egypt, Kuwait, Qatar, U.A.E., Oman, Bahrain, and rest of Middle east and Africa, Brazil, Argentina, and rest of South America.
As per Data Bridge Market Research analysis:
Asia-Pacific is expected to dominate and fastest growing region in global hepatitis B treatment market
Asia-Pacific is expected to dominate and fastest growing region because, technological advancements in diagnostics.
For more detailed information about the Global hepatitis B treatment Market report, click here – https://www.databridgemarketresearch.com/de/reports/global-hepatitis-b-infection-market
